Morgan Stanley raised the firm’s price target on Regenxbio (RGNX) to $25 from $24 and keeps an Overweight rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- REGENXBIO Reports Q3 2025 Financial and Operational Progress
- Regenxbio reports Q3 EPS ($1.20), consensus ($1.30)
- Regenxbio expects cash, equivalents to fund operations into early 2027
- FDA’s ‘surprising’ uniQure reversal drags down Biohaven
- RegenXBio’s Strong Position in Biotechnology Justifies Buy Rating Amid Gene Therapy Uncertainties